Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, ...
Monthly olezarsen reduced triglycerides by 65% for people with severe hypertriglyceridemia, resulting in a greater than 85% ...
MedPage Today on MSN
Novel GLP-1 Drug on Attack Path Against Very High Triglycerides
During an AHA press conference, Li explained that each component of the triple-receptor agonist compensates for side effects ...
An investigational triple agonist that targets fibroblast growth factor 21, glucagon and GLP-1 receptors cut triglyceride ...
Clin Lipidology. 2009;4(4):425-437. Clinical event trials are urgently needed to assess treatment strategies for dyslipidemia management, including POM3 treatment, in patients with ...
Researchers report early but encouraging results on an experimental gene-editing treatment for high cholesterol.
These data were presented today during a late-breaking session at the American Heart Association (AHA) Scientific Sessions and published simultaneously in The New England Journal of Medicine (NEJM) in ...
A CRISPR-based gene therapy showed improvement in lipids in difficult-to-treat patients, but one study raised flags after a ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). In ...
The single dose treatment helped patients lower “bad” cholesterol and triglyerides, both linked to heart disease ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase 3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback